InterveXion Therapeutics

Name

InterveXion Therapeutics

Legal name

InterveXion Therapeutics

Website

https://intervexion.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

InterveXion Therapeutics is a clinical-stage biopharmaceutical company developing IXT-m200, a monoclonal antibody designed to treat methamphetamine use disorder by blocking the drug's euphoric effects. The UAMS-affiliated startup is funded primarily through NIH grants and is conducting Phase 2 trials.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Addiction Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Monoclonal antibody therapy
• Methamphetamine use disorder
• Clinical-stage biopharmaceutical
• Addiction therapeutics
• Anti-drug antibody treatment

Headquarters

HQ city

Little Rock

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. IXT-m200 Drug Development and Commercialization: As a biopharmaceutical company in Phase 2 clinical trials, InterveXion derives revenue from drug development activities. The primary revenue stream will come from commercializing IXT-m200 as a treatment for methamphetamine use disorder upon FDA approval. The company has received NIH grant funding ($13.8 million) to support clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

InterveXion Therapeutics is a clinical-stage biopharmaceutical company developing IXT-m200, a monoclonal antibody drug candidate intended to treat methamphetamine use disorder. The antibody is designed to bind methamphetamine in the bloodstream, preventing it from crossing the blood-brain barrier and thereby reducing or preventing its euphoric effects and overdose risk. The drug is currently in a Phase 2 clinical trial funded by the National Institutes of Health and has received FDA Fast Track Designation.

Differentiator

Problem solved

Functional benefit

Products and services

• IXT-m200

Quantifiable outcome

• Phase 2 clinical trial underway to evaluate efficacy and safety of IXT-m200 for methamphetamine use disorder treatment
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• University of Arkansas for Medical Sciences (UAMS)coreStrategic or Co-development Partner · 1 November 2021InterveXion Therapeutics is a startup affiliated with UAMS, with the company developing its monoclonal antibody treatment at the university. The partnership provides access to research facilities, clinical trial infrastructure, and academic expertise in addiction medicine and biopharmaceutical development.

Scale indicators2 records

Broad incumbents

• Indivior: Indivior is a global specialty pharmaceutical company focused on substance use disorders (notably opioid use disorder with Suboxone). It serves as a broad incumbent comparable to InterveXion given its addiction therapeutics franchise, though it is far larger and does not pursue monoclonal antibody approaches.
• Alkermes: Alkermes develops Vivitrol (naltrexone) for opioid and alcohol use disorders, making it a direct addiction therapeutics incumbent. While Alkermes uses small-molecule depot formulations rather than monoclonal antibodies, it represents the closest large-scale commercial competitor in the substance use disorder treatment market that InterveXion targets.

Emerging players

• BioXcel Therapeutics: BioXcel Therapeutics is a clinical-stage biopharmaceutical company applying AI-driven drug discovery to neuroscience and immuno-oncology, including agitation and addiction-adjacent indications. As a similarly small clinical-stage CNS-focused biotech, it provides a relevant emerging-player comparable for InterveXion in stage, scale, and therapeutic area focus.
• Titan Pharmaceuticals: Titan Pharmaceuticals developed Probuphine, a subcutaneous implant for opioid use disorder, making it directly comparable to InterveXion as a small addiction-focused biotech with a single specialized product strategy. Both companies target underserved substance use disorder populations with novel delivery approaches.
• Opiant Pharmaceuticals: Opiant Pharmaceuticals developed intranasal naloxone (OPVEE) for opioid overdose reversal before being acquired by Indivior. It is comparable to InterveXion as a small clinical-stage addiction therapeutics company pursuing regulatory Fast Track pathways for underserved overdose/addiction indications.
• Camlin Bennett / Anti-Cocaine mAb Programs (academic): Academic anti-drug monoclonal antibody programs (notably Columbia's anti-cocaine mAb work) pursue the same novel mechanism as IXT-m200 — using antibodies to sequester drugs of abuse in the bloodstream. These programs represent direct scientific competitors to InterveXion's platform approach, even if not commercial-stage companies.
• Braeburn Pharmaceuticals: Braeburn Pharmaceuticals focuses on specialty pharmaceutical treatments for opioid use disorder and pain, including Braeburn's Probuphine commercialization efforts. As a small-to-mid specialty pharma focused exclusively on addiction medicine, Braeburn is comparable in therapeutic focus and emerging-stage positioning to InterveXion.
• US WorldMeds: US WorldMeds is a specialty pharmaceutical company focused on addiction, CNS, and rare diseases, with products like Lucemyra (lofexidine) for opioid withdrawal. It serves as an emerging specialty pharma peer to InterveXion given its addiction therapeutics focus and similar target physician base.
• Addex Therapeutics: Addex Therapeutics is a small clinical-stage biopharmaceutical company developing CNS-focused therapeutics, including programs in addiction-adjacent indications. As a similarly small, clinical-stage neuroscience-focused biotech, Addex provides a relevant comparable for InterveXion's stage and capital structure.
• Tonix Pharmaceuticals: Tonix Pharmaceuticals is a clinical-stage CNS-focused biopharmaceutical company with programs in addiction medicine, including cocaine intoxication and overdose. Its CNS-addiction overlap and small-cap clinical-stage profile make Tonix a relevant emerging peer to InterveXion, though Tonix pursues small-molecule rather than mAb approaches.

Market position

Customer concentration

• LinkedInlinkedin.com/company/intervexion-therapeutics-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InterveXion Therapeutics